BioSpace News Archive

Artios Pharma Limited announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

C4 Therapeutics, Inc. today announced that C4T management will participate in a fireside chat at the Stifel 2024 Targeted Oncology Forum taking place virtually from April 16 – April 17, 2024.

ProMIS Neurosciences Inc. today announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, “Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.”

InMode Ltd. announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024.

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression.

Calidi Biotherapeutics Inc. today announced the presentation of new data detailing the molecular mechanisms of action underlying the immunomodulatory role of Calidi’s therapies at the American Association for Cancer Research Annual (AACR) Meeting 2024, in San Diego, California.

GT Medical Technologies, Inc. today announced it has enrolled the 100th patient in its ROADS clinical study. ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).

Sonoma Pharmaceuticals, Inc. today announced the expansion of its Microcyn Negative-Pressure Wound Therapy (NPWT) Solution products in the United States.

Proprio today announced a landmark multi-phase partnership with the Biedermann Group, the prominent innovator in next generation spinal implants with Proprio’s Paradigm system, which harnesses AI, computer vision, and augmented reality to provide unprecedented real-time visualization and guidance to surgeons in the operating room.

Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, announced financial results for the fiscal year ended December 31, 2023.